Aytu Bioscience (NASDAQ:AYTU) Receives “Buy” Rating from Northland Securities

Northland Securities reaffirmed their buy rating on shares of Aytu Bioscience (NASDAQ:AYTU) in a report published on Tuesday morning, AnalystRatings.com reports. They currently have a $10.00 target price on the stock.

“We perceive the co-promotion agreement positively as significantly enhances direct selling of Natesto while placing a higher promotional focus on urologists and endocrinologists. Pre-open, Aytu BioScience announced that it amended its agreement with Acerus Pharmaceuticals, wherein Natesto (testosterone nasal gel spray for the treatment of Low-T) will be co-promoted with Acerus Pharamceuticals. Under the terms of the amended agreement and upon closing, Acerus Pharmaceuticals will launch a complementary US commercial team of at least 25 US-based specialty sales reps that will market Natesto directly to urologists and endocrinologists. This will nearly double the size of the Natesto field salesforce.”,” the firm’s analyst wrote.

A number of other brokerages have also issued reports on AYTU. Zacks Investment Research raised Aytu Bioscience from a hold rating to a strong-buy rating and set a $2.25 price target on the stock in a research note on Friday, May 17th. ValuEngine lowered Aytu Bioscience from a buy rating to a hold rating in a research note on Wednesday, May 1st.

Shares of NASDAQ:AYTU opened at $1.39 on Tuesday. The company has a current ratio of 4.10, a quick ratio of 3.76 and a debt-to-equity ratio of 0.32. The stock has a 50 day moving average price of $1.77. Aytu Bioscience has a 1 year low of $0.68 and a 1 year high of $6.96.

Aytu Bioscience (NASDAQ:AYTU) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.61) by $0.11. The firm had revenue of $2.38 million for the quarter, compared to analyst estimates of $2.00 million. Aytu Bioscience had a negative return on equity of 81.04% and a negative net margin of 184.35%. Research analysts anticipate that Aytu Bioscience will post -2.2 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AYTU. Searle & CO. purchased a new stake in Aytu Bioscience in the first quarter valued at $25,000. Virtu Financial LLC purchased a new stake in Aytu Bioscience in the first quarter valued at $30,000. Finally, Geode Capital Management LLC purchased a new stake in Aytu Bioscience in the fourth quarter valued at $43,000. 15.13% of the stock is currently owned by institutional investors.

Aytu Bioscience Company Profile

Aytu BioScience, Inc, a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and ZolpiMist, an oral spray for the treatment of insomnia.

See Also: Accumulation/Distribution

Receive News & Ratings for Aytu Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.